Alimera Sciences — Corporate Update (June 2022)
20 slides from Alimera Sciences's corporate update, Jun 7, 2022
Slide 1: Corporate Update
Qlimera Corporate Update Rick Eiswirth, President and CEO Date: June 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This slide presentation and Mr. Eiswirth’s in-person presentation that accompanies it may include "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera's belief, expectation, or anti
Slide 3: Investment Thesis
Investment Thesis Unique Asset + Alimera is changing the treatment paradigm as the only non-acute therapy reducing the recurrence of retinal disease Established Commercial Business + Approximately $60 million in consolidated net revenue in 2021 with positive adjusted EBITDA despite COVID-19 impact +
Slide 4: Diabetic Macular Edema (DME)
Diabetic Macular Edema (DME) * The leading cause of vision loss in diabetic patients. * Leaky blood vessels in the macula cause the retina to swell. * Causes blurred vision in the early stage, over long term may cause cumulative damage Qlimera
Slide 5: The ophthalmology standard of care is inconsistent
The ophthalmology standard of care is inconsistent with the way physicians in other disciplines treat persistent or chronic diseases because their options have been limited How Persistent or Chronic Disease is How DME and Non- Infectious Posterior Treated Today Uveitis are Treated Today with Injecti
Slide 6: DME Treatment & Recurrence for a Typical Patient
CRT (microns) DME Treatment & Recurrence for a Typical Patient non a iss a) b (S) (9) iS © J- PPV J- IVTA | oy J DEX — Central Retinal Thickness —Visual Acuity ILUVIEN Qlimera 0.4 20/40 0.35 03 0.25 20/80 0.2 20/100 O.1S O01 20/200 0.05 20/400
Slide 7: ILUVIEN: A Truly Durable Treatment
ILUVIEN®: A Truly Durable Treatment * Provides CONTINUOUS MICRODOSING™ for = Continuous Therapy in Patients with Retinal Disease E Nonbloerodable tube ot polite Internal matrix containing 0.19 mg oy funciisione aceorice * Designed to deliver daily sub microgram levels of FAc for up to three years fr
Slide 8: USER Study
USER Study Reduced disease recurrence Reduced treatment burden Improved and maintained vision Qlimera BEFORE ILUVIEN ! AFTER ILUVIEN 80 1 Treatment Every 2.9 Months ; 1 Treatment Every 22 Months } ———_—_—_——" 70 ' ' 60 1 Treatment Every 2.3 Months 1 Treatment Every 7.0 Months. # Letters Visual Acuit
Slide 9: Alimera Annual Consolidated Revenue
Alimera Annual Consolidated Revenue $46.6 2018 2019 2020 2021 mConsolidated Net Revenue ($Millions) _m License Revenue ($Millions) Qlimera
Slide 10: Financials
Financials Alimera Revenue ($Mio) by Alimera Revenue ($Mio) Pre-COVID Segment $14.0 $12.0 ee $35.0 $10.0 $5.2 ; $30.0 $8.0 inne $25.0 $6.0 $20.0 rea $63.2 Annual Run Rate $4.0 it ies ls $15.0 F ree) dae $2.0 $10.0 $- $5.0 Qi Q2 Q3 Q4 Q122 ’ HU,S, Sales minternational Sales Q4 2019 and Q12020 Alimera
Slide 11: Strategic Overview
Strategic Overview SEE New Physicians Organic and More Patients Growth Treated Earlier NEW DAY Study Option Value Making ILUVIEN Geographic Available in Expansion Additional Countries Adding Uveitis New Indication in EU Indication Markets Qlimera
Slide 12: End User Demand - YTD Through May of Each Year
End User Demand —- YTD Through May of Each Year* *End user demand represents units purchased by physicians and pharmacies from Alimera’s wholesalers and distributors.. 4000 3500 ——— 3000 ea 2500 2000 1500 1000 2019 2020 2021 2022 HU.S. BInternational Direct mInternational Distributor Qlimera R
Slide 13: The New Day Study
The New Day Study A Prospective, Randomized, Controlled Study of the Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients with Early NEW DAY Diabetic Macular Edema STD DY First ever direct head-to-head comparison of a corticosteroid and anti-VEGF therapy (aflibercept) - Assesses ILUVIEN as
Slide 14: The PALADIN Study
The PALADIN Study A phase 4, open-label, prospective, observational study conducted over 36 months at 41 sites across the United States Key Findings 2.97% of eyes required IOP lowering surgery, but only half of these were due to steroid induced ocular hypertension following the administration of ILU
Slide 15: Mean Visual Acuity (VA; Letters)
Mean Visual Acuity (VA; Letters) Vision Improves Even After Three Years of Declining Vision Mean Change in Visual Acuity Pre-FAc | | Mean Change in BCVA Post-FAc 36 31 26 21 16 Months Pre-FAc Mean Visual Acuity (BCVA; Letters) a ILUVIEN Baseline 3 6 9 12 24 36 Months Post-FAc Qlimera All Eyes (n=202
Slide 16: Strategic Geographic Expansion
Strategic Geographic | Expansion Launches in approved markets - intent to continue expanding into new international territories Qlimera 6
Slide 17: Expansion into Greater China & Western Pacific
Expansion into Greater China & Western Pacific Ocumension Therapeutics licensed rights to our intravitreal implant in Q2 2021 * $10 million upfront, up to $89 million in sales-based milestones Milestone $10 million equity investment Alimera received one million non-transferable warrants to purchase
Slide 18: Further Launches for Non-Infectious Uveitis Affecting the Posterior Segment
Further Launches for ; ; Non-Infectious Uveitis Affecting the sane Fitst Posterior Segment of the Eye Active Control [10 ¢ First uveitis label for “prevention”. Further muwiEn de F a supports the uniqueness of ILUVIEN to reduce the recurrence of retinal disease. Oo 50 100 « Estimated market size - 1
Slide 19: Investment Thesis
Investment Thesis Unique Asset + Alimera is changing the treatment paradigm as the only non-acute therapy reducing the recurrence of retinal disease Established Commercial Business + Approximately $60 million in consolidated net revenue in 2021 with positive adjusted EBITDA despite COVID-19 impact +
Slide 20: Alimera
Qlimera Corporate Update Rick Eiswirth, President and CEO Date: June 2022